Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19

資料種別:
論文(リポジトリ)
責任表示:
Nakamura, Hideta ; Miyagi, Kazuya ; Otsuki, Mariko ; Higure, Yuuri ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Haranaga, Shusaku ; Tateyama, Masao ; Fujita, Jiro
言語:
英語
出版情報:
The Japanese Society of Internal Medicine — 一般社団法人 日本内科学会, 2020-11-15
著者名:
Nakamura, Hideta
Miyagi, Kazuya
Otsuki, Mariko
Higure, Yuuri
Nishiyama, Naoya
Kinjo, Takeshi
Nakamatsu, Masashi
Haranaga, Shusaku
Tateyama, Masao
Fujita, Jiro
続きを見る
掲載情報:
Internal Medicine
ISSN:
1349-7235  CiNii Research  Webcat Plus  JAIRO
0918-2918  CiNii Research  Webcat Plus  JAIRO
巻:
59
通号:
22
開始ページ:
2945
終了ページ:
2949
バージョン:
VoR
概要:
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
論文
続きを見る
URL:
http://hdl.handle.net/20.500.12000/47366
電子版
Loading